Photodynamic therapy (“cold laser”) PDT was introduced in 2000 as a less-destructive phototherapy for treating CNV. Treatment involves intravenous administration of the photo-sensitizing drug verteporfin followed by the application of light of a specific wavelength. The light incites a localized photochemical reaction in the targeted area, resulting in CNV thrombosis. Although PDT slows progression, it does not prevent significant vision loss in most eyes with CNV and has been shown to upregulate VEGF in the treatment area. Use of PDT for the management of exudative AMD is now rare, except for the most recalcitrant cases or for eyes with PCV.